SCS Capital Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
SCS Capital Management's DNLI Position: Q3 2026 in Review
SCS Capital Management held its Denali Therapeutics (DNLI) position steady in Q3 2026 at 197,998 shares worth $4.09M. The position accounts for 0.04% of the portfolio, ranked #161.
SCS Capital Management first reported a position in DNLI in Q1 2025 and has held it in 7 quarters since. The position peaked at $5.09M in Q2 2026. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.
- SCS Capital Management held 197,998 shares of Denali Therapeutics worth $4.09M as of Q3 2026.
- SCS Capital Management left its Denali Therapeutics share count unchanged in Q3 2026.
- Denali Therapeutics made up 0.04% of SCS Capital Management's portfolio in Q3 2026, its #161 holding.
- SCS Capital Management first reported a position in Denali Therapeutics in Q1 2025 and has held it in 7 quarters since.
- SCS Capital Management's Denali Therapeutics position peaked at $5.09M in Q2 2026.
- 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.
Based on SCS Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.